Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.